Beam Therapeutics Inc. - Common Stock (BEAM) stock analysis
BEAM · Beam Therapeutics Inc. - Common Stock
Latest recorded price: USD 20.94
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 31.9%, free cash flow margin -257.7%, ROIC -89.5%. The model flags 1 risk signal for this company (1 high severity).
Similar companies in Healthcare
- BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
- Celldex Therapeutics, Inc. (CLDX)
- Corcept Therapeutics Incorporated - Common Stock (CORT)
- CRISPR Therapeutics AG - Common Shares (CRSP)
- Cytokinetics, Incorporated (CYTK)
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)